Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in PIQ?
Proteomics International Laboratories: THE INVESTMENT CASE

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions

Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: PIQ The Big Picture
Richard Lipscombe, MD, Proteomics International Laboratories

Proteomics International Laboratories (ASX:PIQ) managing director, Richard Lipscombe, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

Proteomics is a revenue generating company holding the unique position as having the world's first diagnostic test at a commercialisation stage.

The company has proven technology with patents granted, with an Asian focus and global reach.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future PIQ Company articles
View full PIQ profile

Proteomics International Laboratories Timeline

Related Articles

picture of drug research
February 21 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
stylised picture with web icons meant to denote a web search
May 11 2016
Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
Paradigm Biopharmaceuticals [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
10:00
Find out more from Paul Rennie at Proactive's CEO Sessions.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use